References
- Bell TJ, Panchal SJ, Miaskowski C, et al. (2009). The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med 10:35–42.
- Benyamin R, Trescot AM, Datta S, et al. (2008). Opioid complications and side effects. Pain Phys 11:S105–S20.
- Brenner DM, Chey WD. (2014). An evidence-based review of novel and emerging therapies for constipation in patients taking opioid analgesics. Am J Gastroenterol Suppl 2:38–46.
- Camilleri M, Drossman DA, Becker G, et al. (2014). Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil 26:1386–95.
- Department of Health and Human Sevices (2016), Public Health Service, Food and Drug Administration, Center for Drug Evaulation and Research. Pharmacology/toxicology NDA review and evaluation [NDA 208854, naldemedine tosylate]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208854Orig1s000PharmR.pdf [last accessed 9 Jul 2018].
- Emmanuel A, Johnson M, Mcskimming P, Dickerson S. (2017). Laxatives do not improve symptoms of opioid-induced constipation: results of a patient survey. Pain Med 18:1932–40.
- Fukumura K, Yokota T, Baba Y, Arjona Ferreira JC. (2018). Phase 1, randomized, double-blind, placebo-controlled studies on the safety, tolerability, and pharmacokinetics of naldemedine in healthy volunteers. Clin Pharmacol Drug Dev 7:474–83.
- Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd ed. Boca Raton, FL: Taylor & Francis Group, LLC.
- Nee J, Zakari M, Sugarman MA, et al. (2018). Efficacy of treatments for opioid-induced constipation: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 16:1569–84.e2. doi: 10.1016/j.cgh.2018.1001.1021. [Epub ahead of print].
- Nelson AD, Camilleri M. (2016). Opioid-induced constipation: advances and clinical guidance. Ther Adv Chronic Dis 7:121–34.
- Stern EK, Brenner DM. (2018). Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy. J Pain Res 11:195–9.
- Swegle JM, Logemann C. (2006). Management of common opioid-induced adverse effects. Am Fam Physician 74:1347–54.
- Symproic® (naldemedine) [package insert]. (2018). Florham Park, NJ: Shionogi Inc.
- Thorpe DM. (2001). Management of opioid-induced constipation. Curr Pain Headache Rep 5:237–40.